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The microbiota of the gut has many crucial functions in human health. Dysbiosis of the 65 
microbiota has been correlated to a large and still increasing number of diseases. Recent 66 
studies have mostly focused on analyzing the associations between disease and an 67 
aberrant microbiota composition. Functional studies using (in vitro) gut models are 68 
required to investigate the precise interactions that occur between specific bacteria (or 69 
bacterial mixtures) and gut epithelial cells. As most gut bacteria are obligate or 70 
facultative anaerobes, studying their effect on oxygen-requiring human gut epithelial 71 
cells is technically challenging. Still, several (anaerobic) bacterial-epithelial co-culture 72 
systems have recently been developed that mimic host-microbe interactions occurring in 73 
the human gut, including 1) the Transwell “apical anaerobic model of the intestinal 74 
epithelial barrier”, 2) the Host-Microbiota Interaction (HMI) module, 3) the “Human 75 
oxygen-Bacteria anaerobic” (HoxBan) system, 4) the human gut-on-a-chip and 5) the 76 
HuMiX model. This review discusses the role of gut microbiota in health and disease and 77 
gives an overview of the characteristics and applications of these novel host-microbe co-78 
culture systems.  79 
 80 
Introduction 81 
Anaerobic gut bacteria play a pivotal role in human health and disease, most of which are 82 
strict/obligate anaerobes. Due to the oxygen-sensitivity of these bacteria, it is technically 83 
challenging to study their interaction with oxygen-requiring gut epithelial cells in vitro. 84 
Although many of the bacteria can survive oxygen by mechanisms such as sporulation; 85 














number of different anaerobe-epithelial co-culture systems have been developed. These 87 
co-culture systems allow research of both aerobic (i.e. epithelial) cells and specific strains 88 
of anaerobic bacteria within one system. Development of representative co-culture 89 
systems that can mimic the gastrointestinal ecosystem are valuable tools to study host-90 
microbiota interactions in detail at the mechanistic level. This review will first discuss the 91 
role of the human gut microbiota in health and (gut-related) diseases. Secondly, the 92 
relevance and the applications of the currently-available anaerobe-epithelial co-culture 93 
systems will be discussed. 94 
 95 
 96 
1. The role of the gut microbiota 97 
The human gut contains a wide variety of different microorganisms. Bacteria, viruses, 98 
archaea, yeast and fungi colonize the bowel. 2 The bacterial part of the microbiota is the 99 
most studied and best described of these different microorganisms. 3 The trillions of 100 
bacteria that inhabit the gut of each individual belong to hundreds of different species. 4,5 101 
The composition of the gut microbiota is highly dynamic and different for each human 102 
individual and changes during the course of life. 6 The bacterial phyla Bacteroidetes and 103 
Firmicutes are the most prevalent in adults and together they form the majority of the gut 104 
bacteria. 4,5 The microbiota in the gut has many crucial functions in human health and 105 
affects the host via different host-microbiota interaction pathways. 7-9 For example, 106 
intestinal microbiota enable fermentation of complex non-digestible carbohydrates and 107 
produce short-chain fatty acids (SCFAs), such as acetate, propionate and butyrate. 10,11 108 














prausnitzii and Roseburia species, are major butyrate producers. 12,13 Butyrate is known 110 
to be an important energy source for colonocytes, and is suggested to enhance intestinal 111 
barrier function. 14 Moreover, butyrate is known to possess anti-inflammatory properties 112 
and even possible anti-cancer effects. 10-12,15 In addition, the ‘healthy gut microbiome’ 113 
plays an important role in the development of a balanced immune-system. A certain level 114 
of immunological tolerance exists for the intraluminal bacteria in a healthy gut. Extensive 115 
profiling of the human gut microbiome has shown that several common diseases are 116 
associated with “dysbiosis” of the gut microbiota. The term dysbiosis is often used to 117 
describe a disturbed balance between ‘beneficial’ bacteria with anti-inflammatory 118 
properties and pathobionts with pro-inflammatory properties. Moreover, many diseases 119 
are associated with a decreased diversity of the gut microbiota. 16-18 120 
 121 
For the majority of diseases it remains unclear to which extent the dysbiosis is the cause 122 
or the consequence of the disease and/or treatment. 19 This issue is further complicated by 123 
the fact that many studies investigate the bacterial composition of the fecal material, 124 
which may significantly differ from the bacterial composition attached to the mucosa 125 
(mucosa-associated microbiota, MAM) that may be more directly related to the actual 126 
disease development. 20 Moreover, the bacterial composition and abundance vary 127 
between different parts of the gastrointestinal tract.  128 
 129 
It is well established that the two major forms of inflammatory bowel disease (IBD) – 130 
Crohn’s disease (CD) and ulcerative colitis (UC) – are associated with alterations of the 131 














triggered by the commensal microbiota in a genetically predisposed host. 23-27 Changes in 133 
the gut microbiome seem more apparent in CD than in UC. 28,29 Also, CD patients show a 134 
less diverse microbiota profile than healthy individuals. 30,31 Typically, a decrease in 135 
abundance of Bacteroides and Firmicutes is detected, together with an increase in 136 
proteobacteria and fusobacteria. 22 A consistent observation is a decreased abundance of 137 
butyrate-producing F. prausnitzii and an increased number of Adherent-invasive 138 
Escherichia coli (AIEC) in CD patients. 22,32-36 In addition, an increase of the mucin-139 
degrading bacterium Ruminococcus gnavus has been described. 21 CD patients with 140 
higher numbers of pathobionts, such as E. coli, and lower proportions of F. prausnitzii 141 
have an increased risk of endoscopic recurrent disease after ileal/ileocecal resection. 37,38 142 
Furthermore, CD patients with the lowest abundance of F. prausnitzii often have a less 143 
favorable disease course, with worse disease scores and elevated inflammatory markers. 144 
39
 In line with these observations, the abundance of F. prausnitzii may even function as a 145 
biomarker for predicting disease course in CD patients. 40,41  146 
 147 
Another example of a disease in which an aberrant microbiota composition is observed is 148 
celiac disease. In the duodenum of these patients typically an increase in Bacteroidetes is 149 
detected. 42-45 Also, an association between the gut microbiome and the development and 150 
the progression of intestinal cancer has been described. 46,47 Recent evidence suggests a 151 
relationship between aberrant intestinal microbiota and non-gastrointestinal disorders. It 152 
is increasingly recognized that common metabolic diseases, such as obesity and type 2 153 
diabetes mellitus, are associated with an altered microbiota composition. 48-51 For 154 














muciniphila is associated with a healthier metabolic status. 51 Finally, associations 156 
between an altered microbiota composition and neurologic or psychiatric diseases, such 157 
as anxiety, depression and autism are described. 52,53  158 
 159 
The composition of the gut microbiota is dynamic, complex, and is influenced by both 160 
non-adjustable factors, such as age and geographical location, and adjustable factors, like 161 
diet and medication. 54-56 The strong link between aberrant microbiota with several 162 
common diseases, and the possibility to reshape its composition, makes the microbiota an 163 
attractive target for health improvement. 56,57 As a result of a dysbiotic state of the 164 
intestinal bacteria, host functions, such as the epithelial barrier and an adequate immune 165 
response may be compromised.  166 
 167 
It is apparent that dietary interventions have a strong effect on microbiota composition. 168 
58,59
 The western diet, characterized by high sugar and fat content and low amounts of 169 
dietary fiber, has adverse effects on the microbiota composition, especially in the context 170 
of IBD. 60,61 Certain probiotic (living microorganisms) and prebiotic (non-digestible 171 
polysaccharides) supplements can be used to alter the microbiota composition. 62-65 172 
Moreover, different types of medication have adverse effects on the microbiota 173 
composition. For example, treatment of bacterial infections with antibiotic drugs is 174 
common in modern medicine. However, these drugs should be prescribed in a 175 
conservative way, because of the profound effect of these drugs on the microbiota 176 
composition. 66-68 Similarly, chemotherapeutic agents may have an even more detrimental 177 















 Also, a recent study, combining the data of three large Dutch cohorts, shows that 179 
proton pump inhibitors (PPI’s) negatively modify the microbiota and predispose to 180 
Clostridium difficile infection. 71 ‘Improving’ the composition of the gut microbiota is 181 
therefore a promising target for the treatment of many diseases. For C. difficile infection, 182 
fecal microbiota transplantation (FMT) has already been shown to be an effective and 183 
highly successful treatment. 72,73 However, FMT has shown to be less promising for IBD 184 
patients. 74 Moreover, FMT has several risks, such as potential transmission of viruses. 185 
Also the long-term effects of this treatment are not fully determined yet. Multiple studies 186 
have evaluated the effect of prebiotic and probiotic interventions in IBD. In this review 187 
we will only discuss a selection of important studies performed in this area. 75  188 
 189 
In UC the role of the probiotic supplement VSL#3 was evaluated. This supplement is a 190 
probiotic mixture, consisting of four strains of Lactobacillus, three strains of 191 
Bifidobacterium and one strain of Streptococcus salivarius subsp. thermophilus. VSL#3 192 
intake results in an increase of ‘protective’ bacteria and may help to prevent a flare-up of 193 
intestinal inflammation. 76 Indeed, a recent meta-analysis revealed that VSL#3, when 194 
added to conventional therapy, improves remission rates in mild to moderate active UC. 195 
In a similar way, this probiotic mixture enhanced remission in chronic pouchitis patients. 196 
77,78
 Also in CD, the other major form of IBD, different dietary interventions (i.e. pre- and 197 
probiotics) aiming to modify the microbiota composition have been performed. The 198 
clinical trials with pre- and probiotics can be considered as rather opportunistic as they 199 
test the “known suspects” for their therapeutic potential. However, in many cases the 200 














genetic variation and differences in environmental circumstances, are frequently 202 
encountered in prospective human studies. Of course, these factors influence the outcome 203 
of these intervention studies, and may compromise the reliability of the findings. 204 
Considering the ethical issues and high costs associated with such clinical trials, it would 205 
be of immense value when the potential therapeutic effects of pre- and probiotics could 206 
be analyzed in a controlled and reproducible manner. Gnotobiotic animals, such as germ-207 
free mice, seem to be an attractive model between human clinical studies and in vitro 208 
models. 80,81 Advantages of these germ-free mice consist of a controllable host 209 
environment and the opportunity to investigate specific bacterial contributions.  However, 210 
in recent years, many in vitro gut systems have undergone great technological 211 
improvements and increasingly become more representative of the in vivo situation. 212 
These improvements in in vitro gut models will likely result in increased usage of these 213 




2. Gastrointestinal in vitro model systems 218 
Studies that establish an association between a specific microbiota composition and a 219 
disease phenotype provide incomplete information about possible underlying 220 
mechanisms. 86 In vitro studies are often required to give more mechanistic insight. The 221 
complex interactions between human gut microbiota, epithelial cells and immune cells 222 
are difficult to mimic in in vitro models, and also other factors, such as variable oxygen 223 
levels and gut peristalsis should be included. A major advantage of in vitro models is that 224 














mechanistic analysis; have limited ethical restrains and require no expensive and time-226 
consuming ethical approval procedures (as required for human clinical trials or animal 227 
studies). Furthermore, since pharmaceutical procedures and dietary research usually take 228 
many years, a representative in vitro model may considerably accelerate these procedures. 229 
Altogether, this makes the development of in vitro models that closely resemble the 230 
conditions in the gastrointestinal tract highly relevant.  231 
 232 
Exactly mimicking the gastrointestinal situation in vitro seems hardly possible; some 233 
parameters will typically be omitted in the development of a model that is suitable to 234 
answer specific questions. Thus, the research questions to be answered largely determine 235 
which in vitro model is most appropriate to use, although all currently available systems 236 
have their specific limitations as well. Ideally, the in vitro model should allow the 237 
analysis of the direct interactions between host cells and microbes, as it exists in the gut. 238 
Direct host-microbe interactions may be more relevant in the small intestine, with a rather 239 
thin mucus layer compared to the colon where the much thicker mucus layer is a more 240 
prominent physical barrier. The gut lumen is almost completely anaerobic. Only minute 241 
amounts of oxygen will penetrate from the epithelium into the lumen. Thus, the gut 242 
microbiome consists of facultative and (predominantly) strict anaerobic bacteria. An in 243 
vitro model of the gut therefore preferably establishes true anaerobic conditions for the 244 
microbes, while the host cells are cultured under aerobic conditions. Ideally, an in vitro 245 
gut model allows the analysis of parameters that differentiate between health and disease, 246 
as well as the effect of (dietary) interventions. Host parameters that are considered to be 247 














(barrier function) and cytokine production. On the luminal side, microbial parameters, 249 
such as bacterial fitness, bacterial composition, substrate utilization and metabolite 250 
production (such as SCFAs) are important to analyze. The currently available in vitro 251 
models of the human gastrointestinal tract are discussed in the following sections. These 252 
models can be divided into models that enable the study of isolated components of the 253 
gut ecosystem, such as gut epithelium cells and mucosa (section 2.1) or models that study 254 
the gut microbiota in isolation (section 2.2). However, to truly mimic the mutual 255 
communication between human gut (epithelial) cells and the gut bacteria, systems are 256 
needed that allow co-culturing of both in one system, which are reviewed in section 2.3.  257 
 258 
2.1 Models for gut epithelium and mucosa 259 
Intestinal cell lines, such as Caco-2, HT-29, T-84 and DLD-1, are frequently used as 260 
representatives of the human gastrointestinal epithelium, however, they originate from 261 
gastrointestinal tumors. Their true epithelial characteristics are often compromised. Still, 262 
epithelial cell lines can be used in Ussing chamber experiments, in which properties like 263 
transport of substances and permeability through the epithelial cell layer can be assessed. 264 
Intestinal explants have the advantage that the integrity of the intestinal mucosa layer 265 
remains intact. 87,88 Also, precision-cut intestinal tissue slices (PCIS) are an ex vivo model 266 
used for drug metabolism studies. 89,90 All cell types from the gut are present in PCIS and 267 
this model also allows study of diseased tissue. 91 More recently, intestinal organoids or 268 
‘mini guts’ are being established as models of the human intestinal epithelium that 269 
contain all main types of epithelial cells, e.g. enterocytes, goblet cells, enteroendocrine 270 














cells in the gut and remain genetically stable in culture for many cell divisions (over 272 
months to years). 93 Also, the gut organoids maintain their location-specific 273 
characteristics, so a differentiation can be made between colonic, ileal, jejunal and 274 
duodenal primary human intestinal epithelium. 94 Models using epithelial cells can be 275 
exposed to bacteria or bacterial extracts or products secreted by bacteria. However, this is 276 
different from a co-culture device, in which different cell types are grown (and remain 277 
viable) for a certain time period. Also, a potential effect of the epithelial cells towards the 278 
bacteria cannot be studied in such a cell model system.  279 
 280 
2.2 Models for gut bacteria 281 
Examples of systems that are used to study the human gut microbiota in isolation are the 282 
TNO dynamic in vitro model of the human large intestine (TIM-2), the Simulator of the 283 
Human Intestinal Microbial Ecosystem (SHIME), the “Three stage continuous culture 284 
system”, the Lacroix model and the fecal minibioreactor arrays (MBRAs). 95-98 The TIM-285 
2 is designed to simulate the conditions found in the proximal colon. 99 Accumulation of 286 
metabolites in the lumen is prevented by constant and active removal of these metabolites 287 
by means of a dialysis system. In addition, peristalsis, temperature and pH are controlled 288 
in this system to mimic the in vivo human situation. The TIM-2 system allows for the 289 
analysis of fermentation patterns and effects of prebiotic and probiotic supplement intake 290 
on microbial composition. 100-105 The SHIME contains five connected vessels that are 291 
designed to closely mimic the bacterial compartment of the gastrointestinal tract of an 292 
adult human. 106 Each reactor simulates a different part of the GI-tract: stomach, small 293 














‘intraluminal content’ is continuously stirred and pH-controlled. In addition, pancreatic 295 
enzymes and bile are added to more closely resemble the in vivo situation. In this model 296 
the fermentation patterns of four polysaccharides were shown to be similar to the 297 
fermentation pattern that occurs in vivo. 107  The SHIME is relevant for intervention 298 
studies, such as supplementation studies of different probiotic strains or prebiotics. 108-110 299 
The “Three stage continuous culture system” comprises three culture vessels, simulating 300 
the ascending, transverse and descending colon. This system simulates the nutritional and 301 
environmental conditions in the human large intestine. Oxygen-free conditions, pH 302 
control and transit time closely resemble the in vivo situation. 95,111,112 The Lacroix model 303 
is also a three stage continuous culture system, which uses immobilized fecal microbiota 304 
and is used to simulate fermentation of the infant colon. 97,113 Finally, the fecal 305 
minibioreactor array (MBRA) is another in vitro system used to cultivate and investigate 306 
fecal microbiota communities. In these bioreactors, consisting of six single vessel 307 
chambers in an anaerobic chamber, the diluted feces of multiple human donors is used. In 308 
one study this system is used to test competition between different ribotypes of C. 309 
difficile. 98  310 
 311 
The systems described above may generate valuable information about the response of 312 
the gut mucosa to bacterial (products) or direct effects of nutritional factors to the 313 
composition of the gut microbiota. However, they do not allow the analysis of the mutual 314 
communication between the gut bacteria and the intestinal epithelium or simulate disease 315 














is to co-culture bacteria under anaerobic conditions while gut (epithelial) cells are 317 
provided with sufficient oxygen. 318 
 319 
2.3 Models for gut host-microbe interactions 320 
An in vitro gut host-microbe co-culture system would have many advantages for 321 
unraveling the direct role of gut bacteria in intestinal health, provided that it is robust and 322 
truly simulates the gut ecosystem. A schematic figure of the host-microbe interaction at 323 
the aerobe-anaerobe interphase is shown in Figure 1A. Below, we give a concise 324 
overview of recently developed systems that enable the co-culture of (anaerobic) gut 325 
bacteria and (oxygen-requiring) epithelial cells (also see Table 1 for a comparative 326 
overview).  327 
I) Transwell co-culture models are examples of systems that are used to study cell-cell 328 
interaction. These Transwell co-culture systems seem to be particular useful to study the 329 
interaction between bacteria, mucosal immune cells and intestinal epithelial cells under 330 
static conditions, but are more frequently used under aerobic conditions. 114-116 Recently, 331 
a custom-made variant of such a ranswell co-culture system was developed that allows 332 
the analysis of host-microbe interactions between oxygen-requiring Caco-2 cells and 333 
anaerobic F. prausnitzii bacteria for up to 8 h. 117 The Transwell ‘apical anaerobic 334 
model of the intestinal epithelial barrier’ chamber (see Figure 1B) contains oxygen-335 
containing medium in the bottom compartment. Caco-2 cells pre-grown on the filter of an 336 
insert are placed in the chamber. Subsequently, anaerobic culture medium, with or 337 
without F. prausnitzii, is added in the insert allowing direct contact with the Caco-2 cells. 338 














levels remained high in the bottom compartment and low in the upper compartment over 340 
a 12 h incubation period. F. prausnitzii bacteria pre-grown to stationary phase were 341 
added in anaerobic host cell culture medium (M199) to the upper compartment. The 342 
number of viable F. prausnitzii remained relatively stable, but still dropped 343 
approximately 10-fold after an 8 h co-culture period with Caco-2 cells. In comparison, 344 
viability of F. prausnitzii dropped over 10,000-fold when cultured for 30 min in oxygen-345 
containing M199. During 8 h of co-culturing, Caco-2-dependent transepithelial electrical 346 
resistance (TEER) was slightly enhanced by F. prausnitzii compared to control 347 
conditions without bacteria. The 3H-mannitol flux across the Caco-2 monolayer was not 348 
affected by F. prausnitzii during the first 6 h of co-culture, after which it increased in 349 
comparison to control conditions without bacteria. Global gene expression analysis of 350 
Caco-2 cells exposed for 4 h to either live or UV-killed F. prausnitzii revealed that live 351 
bacteria suppress cellular pathways involved in inflammatory response and immune cell 352 
trafficking much stronger than dead bacteria. The most pronounced findings were the 353 
increase in IL-10 and a decrease in NF-κB signaling. Thus, the ‘apical anaerobic model 354 
of the intestinal epithelial barrier’ maintains (sufficient) viability of host cells and 355 
microbes for up to 8 h, allowing real time measurements of TEER. In addition, it shows 356 
that the metabolic activity of F. prausnitzii is required to acquire its maximum anti-357 
inflammatory capacity.  358 
II) The Host-Microbiota Interaction (HMITM) module is a custom-made co-culture 359 
system consisting of two compartments, a “luminal” compartment containing gut bacteria 360 
and a “host” compartment containing the “enterocytes”, e.g. Caco-2 cells (see Figure 361 














that these two compartments have (semi-)continuous flow of fluid and are separated by a 363 
functional double layer (a semi-permeable membrane and an artificially added mucus 364 
layer). The HMI module was designed to be connected to an adapted version of the 365 
SHIME, containing only the first 3 reactors that simulate the stomach, the small intestine 366 
and the ascending colon. The SHIME was inoculated with a fecal sample of a healthy 367 
individual and after passing the 3 reactors the effluent, consisting of a complex mixture 368 
of intestinal bacteria, flows through the “luminal” compartment of the HMI module. The 369 
“host” compartment containing Caco-2 cells receives semi-continuous flow of cell 370 
culture medium in the opposite direction. The separating layer (semi-permeable 371 
polyamide membrane with 0.2-µm pore size coated with a mucus layer) was shown to be 372 
permeable for FITC-dextran of up to 150 kDa in size, but obviously does not allow direct 373 
interaction between bacteria and host cells. In this co-culture system, important features 374 
of the gastrointestinal tract, such as shear stress, permeability, oxygen diffusion and the 375 
possibility of the microbiota to colonize the mucus layer are taken into account to closely 376 
mimic the human in vivo situation. In addition, a dietary intervention using the dried 377 
fermentation products of baker’s yeast (Saccharomyces cerevisiae) was studied in this 378 
system. Caco-2 cells appeared very sensitive to direct exposure to the effluent of the 379 
adapted SHIME leading to a 80% reduction in cell viability after 2 h. In contrast, Caco-2 380 
cells remained viable for up to 48 h when cultured in the HMI module downstream of the 381 
SHIME. The SHIME-HMI combined system was used to study the effect on the luminal 382 
and mucosa-associated microbiota, as well as on Caco-2-mediated cytokine production 383 
upon treatment with fermentation products of S. cerevisiae. The presence of Caco-2 cells 384 














bacterial groups in the luminal samples, although a consistent trend of reduced bacterial 386 
numbers was observed in time (comparing 0, 24 and 48 h co-culturing). The treatment 387 
with S. cerevisiae fermentation products significantly enhanced the levels of SCFAs in 388 
the SHIME effluent entering the HMI module. Remarkably, this was associated with a 389 
lower total number of luminal bacteria, similar for all four groups tested. Passing the S. 390 
cerevisiae-treated effluent through the Caco-2-containing HMI module resulted in a 391 
significant increase in the abundance of luminal Bacteroidetes, Firmicutes and 392 
bifidobacteria. Interestingly, Caco-2 cells produced significant amounts of pro-393 
inflammatory IL-8 at the end of the 48 h co-culturing with the normal SHIME effluent, 394 
which was completely suppressed by the treatment with S. cerevisiae fermentation 395 
products, indicating an anti-inflammatory response induced by this “intervention”. This is 396 
in line with immune modulating / anti-inflammatory properties of this product that have 397 
previously been demonstrated in in vivo studies. 119-121 A reduction of pro-inflammatory 398 
IL-8 production was correlated with an increased butyrate production in the SHIME. 122 399 
Interestingly, this intervention resulted in a 31% increase in butyrate production in the 400 
ascending colon of the HMI module. Simultaneously, the HMI module allows for the 401 
analysis of the bacterial colonization of the mucus layer. While the strict anaerobic 402 
bifidobacteria colonized the upper side of the mucus layer (facing the luminal 403 
compartment), F. prausnitzii was mainly detected in the lower parts of the mucus (facing 404 
the “host” compartment) as observed in the human gut in vivo. This may be due to the 405 
capability of F. prausnitzii to survive microaerophilic conditions in the abundant 406 














III) The 3rd system that aims to simulate host-microbe interactions occurring at the oxic-408 
anoxic interphase of the (human) gut is the ‘Human oxygen Bacteria anaerobic’ 409 
(HoxBan) co-culturing system (see Figure 1D). In contrast to the previously described 410 
“apical anaerobic model of the intestinal epithelial barrier” and HMI module, the HoxBan 411 
system does not require specialized (e.g. custom-made) equipment. The HoxBan system 412 
consists of an anaerobic and an aerobic compartment that are created in a 50 mL plastic 413 
tube. The bottom compartment contains the anaerobic bacteria of interest in specific 414 
culture medium solidified with 1% agar. The top compartment contains the oxygen-415 
requiring epithelial cells on a glass coverslip (cells facing down), covered with cell 416 
culture medium. Oxygen is penetrating in the agar from the top compartment, creating an 417 
oxygen gradient, resembling the steep gradient across the human intestinal epithelium. 418 
Obligate anaerobic bacteria in the lower compartment are protected from oxygen by the 419 
agar and can grow at the lower end of the gradient. 123 In practice, the liquid (hand-warm) 420 
agar broth is inoculated with F. prausnitzii in an anaerobic workstation, aliquoted (40 mL 421 
each) in 50 mL plastic tubes and allowed to solidify. Subsequently, the HoxBan tubes are 422 
transferred to a cell culture cabinet and Caco-2 cells, pre-grown on coverslips to 80-100% 423 
confluency, are placed upside-down on the bacteria-containing agar medium. The tubes 424 
are filled to the top with cell culture Dulbecco’s Modified Eagle Medium (DMEM). 425 
Subsequently, the tubes are placed in a standard humidified cell culture incubator at 37oC 426 
and 5% CO2 for up to 18-36 h. No reduction in viability of Caco-2 cells was observed 427 
when co-cultured with F. prausnitzii for 24 h. In fact, this analysis showed for the first 428 
time that mutualism is observed between oxygen-requiring intestinal epithelial (Caco-2) 429 














growth was observed directly below the Caco-2-containing coverslips. Interestingly, this 431 
was not seen when F. prausnitzii was co-cultured with non-intestinal cells, like the 432 
human liver cancer cell line HepG2, indicating that this effect is (intestinal) cell type-433 
specific. Moreover, Caco-2-F. prausnitzii co-cultures in the HoxBan system confirmed 434 
the anti-inflammatory and anti-oxidative stress effects of live F. prausnitzii on Caco-2 435 
cells. The HoxBan setup allowed analyses of the consumption and production of 436 
metabolites (the “exo-metabolome”, including SCFAs, hydrocarbons, lipids and amino 437 
acids) in the liquid cell culture medium after 18 h of co-culture. These analyses revealed 438 
that levels of formate are strongly increased if F. prausnitzii is co-cultured with Caco-2 439 
cells, while butyrate levels are not changed (compared to F. prausnitzii without Caco-2 440 
cells). The selective effect on the levels of these SCFAs requires further study, but could 441 
be a result of the selective use of butyrate by the “enterocytes”. Currently, research in 442 
additional applications of the HoxBan system is being performed. These include studies 443 
assessing the effect of prebiotic and vitamin interventions on host-microbiota interplay 444 
and adaptation of this system to a disease model for IBD. The results observed in the 445 
HoxBan model correspond with previously performed in vivo studies. Anti-inflammatory 446 
effects of this bacteria were demonstrated in a murine TNBS-induced (chemical induced) 447 
colitis model, in which administration of F. prausnitzii and its supernatant had a 448 
protective effect. 124 Also a beneficial effect of F. prausnitzii on intestinal epithelial 449 
barrier function has been described in a murine model of low-grade inflammation. 125 450 
Furthermore, a large meta-analysis in 2014 showed that the abundance of F. prausnitzii is 451 














IV) A 4th system that is relevant for host-microbe interaction studies is the human gut-453 
on-a-chip (see Figure 1E). However, in contrast to the previously described systems, its 454 
use for co-culturing human cells with strict anaerobic gut bacteria has not been performed 455 
yet and it may be technically very challenging to maintain both aerobic and (strict) 456 
anaerobic conditions in this system. Still, very interesting results were obtained when co-457 
culturing Caco-2 cells with oxygen-tolerant gut bacteria, which may be relevant for 458 
further development of true aerobic-anaerobic co-culturing systems. The gut-on-a-chip 459 
consists of two microchannels, simulating the gut lumen and the blood compartment, 460 
separated by a porous flexible membrane coated with extracellular matrix (ECM) and 461 
lined by Caco-2 cells. 126 Apart from continuous medium flow providing low shear stress 462 
to Caco-2 cells, this system is unique because of the fact that it can also mimic 463 
peristalsis-like motions by stretching and relaxing the ECM-coated porous membrane. 464 
This membrane is attached to two hollow side chambers that are rhythmically 465 
inflated/deflated. Especially promoted by the peristalsis-like motions, Caco-2 cells 466 
differentiate into a complex intestinal epithelium consisting of four types of intestinal 467 
epithelial cells, i.e. absorptive enterocytes, mucus-secreting goblet cells, enteroendocrine 468 
cells and Paneth cells. Moreover, 3D villi-like structures are formed. 126,127 The gut-on-a 469 
chip allows the analysis of TEER, which increased more rapidly compared to 470 
monocultured Caco-2 cells in transwell cultures. Gut-on-a-chip allows the long-term 471 
(days up to two weeks) co-culture with bacteria. Probiotic Lactobacillus rhamnosus GG 472 
(LGG) formed microcolonies on the surface of Caco-2 cells and increased the TEER 473 
compared to Caco-2 cells not exposed to LGG. Co-culturing of Caco-2 cells with a 474 














isolated from the human gut microbiome) for 72 h induced transcriptome changes in 476 
Caco-2 cells that more closely resemble the human ileum, as compared to monocultured 477 
Caco-2 cells in the gut-on-a-chip. Moreover, VSL#3, as well as antibiotic therapies, were 478 
shown to suppress villus injury and loss of TEER was induced by pathogenic Entero-479 
invasive E. coli (EIEC) bacteria. Interestingly, exposure to LPS isolated from pathogenic 480 
E. coli did not directly affect TEER or villus injury in Caco-2 cells in the gut-on-a-chip. 481 
Only when human peripheral blood mononuclear cells (PBMCs) were also included in 482 
the lower capillary channel (simulating the blood compartment), both loss of TEER and 483 
villus injury were induced by LPS. Moreover, inclusion of PBMCs and LPS in the gut-484 
on-a-chip resulted in the polarized secretion of inflammatory cytokines (IL-1β, IL-6 and 485 
TNFα) to the “blood compartment”. Finally, the manipulation of peristaltic motions 486 
appeared to be highly relevant for host-microbe interactions, where the absence of such 487 
cyclic mechanical deformations increased the levels of E. coli colonizing the enterocyte 488 
surface, a process that might resemble bacterial overgrowth. As highlighted before, strict 489 
anaerobic bacteria have not been co-cultured with Caco-2 cells in the gut-on-a-chip and 490 
given the small diameters of the channels it may be technically impossible to maintain 491 
anaerobic conditions in the “luminal compartment”.  492 
V) The 5th and most recently described aerobic-anaerobic co-culture system is the 493 
HuMiX (human-microbial crosstalk) modular microfluidic device. 128 This device is 494 
composed of a modular stacked assembly of elastomeric gaskets sandwiched between 495 
two polycarbonate enclosures (see Figure 1F). Each gasket defines a distinct spiral-496 
shaped microchannel. The upper compartment is the ‘Microbial microchamber’ and is 497 














Nanoporous membrane (pore diameter 50 nm). The ‘Epithelial cell microchamber’ 499 
contains the oxygen-requiring Caco-2 cells, forming the epithelial cell barrier. The 500 
bottom microchannel is the ‘perfusion microchamber’, which is separated from the 501 
‘Epithelial cell microchamber’ by a Microporous membrane (pore diameter 1 µm). In this 502 
device, Caco-2 cells are first cultured and grown for 7 days to form a well-differentiated 503 
layer of epithelial cells. Monocultured Caco-2 cells established significantly higher 504 
TEER in the HuMiX as compared to Caco-2 cells cultured in a similar set-up in a 505 
Transwell device. Moreover, clear expression of the tight junction protein occludin at the 506 
cellular membrane was demonstrated by immunofluorescence microscopy. Subsequently, 507 
bacteria were inoculated in the Microbial microchamber and co-cultured for an additional 508 
24 hours. Following co-culture, all individual cell contingents can easily be accessed and 509 
evaluated. In this study, the researchers first inoculated the commensal facultative 510 
anaerobe Lactobacillus rhamnosus GG (LGG), which was also studied in the gut-on-a 511 
chip (see above). Both the oxygen-requiring Caco-2 cells and the facultative anaerobe 512 
LGG remain viable during co-culture. Integrated oxygen sensors in this device allow the 513 
real time monitoring of dissolved oxygen concentrations. Clearly different oxygen levels 514 
were detected between the “perfusion microchamber” and the “microbial microchamber”, 515 
though the latter was not completely devoid of oxygen. Still, the authors show that this 516 
device can also be used to study the effect of obligate anaerobic bacteria in co-culture 517 
with Caco-2 cells. The obligate anaerobic strain Bacteroides caccae (of the phylum 518 
Bacteroidetes) inoculated in combination with LGG remained viable and a relative 519 
increase in number of B. caccae compared to LGG was detected after a 24 hour co-520 














after co-culture were not shown. Moreover, the potential difference in growth rate 522 
between these two bacteria (in the absence of Caco-2 cells) was not established. So a 523 
potential selectivity of Caco-2 cells towards specific bacteria cannot be concluded from 524 
these experiments. Importantly, this device allows the additional inclusion of immune 525 
cells (i.e. CD4+ T cells) to the perfusion chamber, to help further clarify specific 526 
immunological research questions. Finally, the authors validate the HuMiX in relation to 527 
previously performed in vivo studies. They show that the transcriptional responses of the 528 
epithelial cells co-cultured with LGG in the HuMiX are in line with in vivo expression 529 
data obtained from human and piglet studies. 129-131 This study nicely demonstrates that it 530 
is crucial to establish (near) anaerobic conditions for the microbiota in a representative 531 
gastrointestinal co-culture device, since clear differences in transcriptional responses 532 
between LGG grown under aerobic and anaerobic conditions were shown. 533 














Table 1. Characteristics and applications of recently developed (anaerobic) bacterial-epithelial gut co-culture models. 
 A. Transwell 
‘apical anaerobic 











E. The HuMiX 
model 
Human gut epithelium 
model (cell type) Caco-2 Caco-2 Caco-2, DLD-1 Caco-2 Caco-2 
Direct contact bacteria and 
host cells Yes 





No (separated by 
Nanoporous 
membrane) 





production) Yes (mucin layer) 
“Gut epithelial cells” 
grown in: 
(during co-culturing) 








broth for SHIME 
YCFAG (Anaerobic 
F. prausnitzii broth) 






Up to 8 h 
Up to 48 h 
connected to 
SHIME  
Up to 36 h 1-2 week  24 h 
Static or fluid flow (shear 
stress) Static 
Fluid flow 





(30 uL h-1= 
0.02 dyne cm
-2) 
Flow rate: 25 µl 
min -1 
Simulation of peristalsis No No No Yes No 
Co-culture with strict 
anaerobic bacteria 





Yes (i.e. F. 
prausnitzii) Not described 
Yes (Bacteroides 
caccae) 
Mixed bacterial cultures Not described 
Yes (fecal inoculum 
from healthy human 
in SHIME) 
Not described Yes (VSL#3) LGG and B. caccae 
Combination with other 
types of (human) cells Not described Not described Not described 
Yes (PBMCs, 
endothelial cells) Yes CD4+ T cells 








150 kDa FITC 
dextran) 
Yes (staining for TJ 
proteins) Yes (TEER) 
Yes (HuMiX-TEER 
device and Staining 
for TJ protein 
occludin) 
Intervention studies (diet, 
medication, etc) Not described 








LGG is used as a 
probiotic treatment 
Model of disease Not described Not described 
Yes (induction of 
inflammatory state 





Abbreviations: Caco-2: human colon epithelial cell line. DLD-1: human colon epithelial cell line. M199: 535 
medium 199. DMEM: Dulbecco’s Modified Eagle Medium. YCFAG: medium containing yeast extract, 536 
casitone, fatty acids and glucose. FBS: fetal bovine serum. H: hours. PBMCs: peripheral blood 537 
mononuclear cells. TEER: transepithelial electrical resistance. TJ proteins: tight junctions proteins. LGG: 538 














Concluding remarks  540 
Dysbiosis of the gut microbiota is associated with many common diseases, however 541 
limited tools are available to determine what is the cause or consequence of this 542 
phenomenon. In vitro models for host-microbe interactions occurring in the (largely 543 
anaerobic) gut are instrumental to analyze the molecular and cellular mechanisms 544 
involved. Several (anaerobic) bacteria-gut epithelial co-culture systems models have 545 
recently been developed. A comparative overview of the characteristics and applications 546 
of these systems is given in Table 1. Each of these systems has its own pros and cons, 547 
and the specific research question will largely determine which system is most suitable to 548 
use. Key factors to consider are 1) whether a strict anaerobic compartment for gut 549 
bacteria is required; 2) whether single or complex mixtures of bacteria need to be 550 
analyzed; 3) whether direct contact with bacteria and gut epithelial cells is important, 4) 551 
whether analysis of the barrier function (such as TEER) is needed; 5) whether effects on 552 
both gut epithelia, as well as bacterial metabolism will be analyzed; and maybe at least as 553 
important 6) whether the equipment and infrastructure is available to perform such 554 
experiments. A major “weakness” of all systems so far is that they all rely on the use of 555 
Caco-2 cells as representative of the human gut epithelium. Still, Caco-2 cells originate 556 
from heterogeneous human epithelial colorectal adenocarcinoma and may therefore 557 
behave quite differently as compared to true human gut epithelium. Recent advancements 558 
in generating primary human epithelium from intestinal stem cells hold great promise for 559 
“upgrading” these host-microbe co-culturing systems with location-specific and/or 560 
disease-specific human gut epithelium. Thus, co-culturing oxygen-requiring human gut 561 














systems need further refinement to help us unravel the complex functional links between 563 
disease and gut microbiome dysbiosis. 564 
 565 
 566 















FIGURE 1 569 
 570 
Figure 1. Recently developed (anaerobic) bacterial-epithelial gut co-culture models. A) Schematic 571 
figure of the aerobe-anaerobe interphase of the human gut (adapted from Barbosa T. et al.; Wiley 572 
Interdiscip Rev Syst Biol Med, 2010)  132 ; B) The Transwell ‘apical anaerobic model of the intestinal 573 
epithelial barrier’ 117 ; C) The Host Microbiota Interaction module (HMITM module) 118 ; D) The 574 
Human Oxygen-Bacteria anaerobic (HoxBan) co-culture system 123 ; E) The human gut-on-a-chip 575 
microdevice 127 and F) The HuMiX device. 128 See main text for detailed description. All models are 576 
shown with permission of the authors when this is required. 577 
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